Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, June 29, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) announces the following blocklisting six monthly return:
| 1. | Name of applicant: | HUTCHMED (China) Limited | ||
| 2. | Name of scheme: | (a) | Share Option Scheme conditionally adopted by HUTCHMED in 2005 (“2005 HUTCHMED Share Option Scheme”) | |
| (b) | Share Option Scheme conditionally adopted by HUTCHMED in 2015 (“2015 HUTCHMED Share Option Scheme”) | |||
| (c) | Warrant instrument granted by HUTCHMED on June 25, 2020 (“Warrant”) | |||
| 3. | Period of return: | From December 29, 2020 to June 28, 2021 | ||
| 4. |
Balance under scheme from previous return:
|
(a) | 2005 HUTCHMED Share Option Scheme: 1,338,910 ordinary shares of US$0.1 each | |
| (b) | 2015 HUTCHMED Share Option Scheme: 53,271,648 ordinary shares of US$0.1 each | |||
| (c) | Warrant: 16,666,670 ordinary shares of US$0.1 each | |||
| 5. |
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
|
(a) | 2005 HUTCHMED Share Option Scheme: Nil | |
| (b) | 2015 HUTCHMED Share Option Scheme: Nil | |||
| (c) | Warrant: Nil | |||
| 6. |
Number of securities issued/allotted under scheme during period:
|
(a) | 2005 HUTCHMED Share Option Scheme: 400,000 | |
| (b) | 2015 HUTCHMED Share Option Scheme: Nil | |||
| (c) | Warrant: Nil | |||
| 7. |
Balance under scheme not yet issued/allotted at end of the period
|
(a) | 2005 HUTCHMED Share Option Scheme: 938,910 ordinary shares of US$0.1 each | |
| (b) | 2015 HUTCHMED Share Option Scheme: 53,271,648 ordinary shares of US$0.1 each | |||
| (c) | Warrant: 16,666,670 ordinary shares of US$0.1 each | |||
| 8. |
Number and class of securities originally listed and the date of admission:
|
25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company’s previous block admission schemes following the Company’s share subdivision which took effect on May 30, 2019) | ||
| 9. | Total number of securities in issue at the end of the period: | 744,515,660 ordinary shares of US$0.1 each | ||
| Name of contact: | Christian Hogg | |||
| Address of contact: | Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong | |||
| Telephone number of contact: | +852 2121 8200 | |||
HUTCHMED (Nasdaq/AIM: HCM) (formerly Hutchison China MediTech) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Investor Enquiries |
|
| Mark Lee, Senior Vice President |
+852 2121 8200 |
| Annie Cheng, Vice President |
+1 (973) 567 3786 |
Media Enquiries |
|
| Americas | |
| Brad Miles, Solebury Trout |
+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com |
| Europe | |
| Ben Atwell / Alex Shaw, FTI Consulting |
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) HUTCHMED@fticonsulting.com |
| Asia | |
| Joseph Chi Lo, Brunswick |
+852 9850 5033 (Mobile) |
| Zhou Yi, Brunswick |
+852 9783 6894 (Mobile) HUTCHMED@brunswickgroup.com |
Nominated Advisor |
|
| Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited |
+44 (20) 7886 2500 |